Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22.
McComb S, Arbabi-Ghahroudi M, Hay KA, Keller BA, Faulkes S, Rutherford M, Nguyen T, Shepherd A, Wu C, Marcil A, Aubry A, Hussack G, Pinto DM, Ryan S, Raphael S, van Faassen H, Zafer A, Zhu Q, Maclean S, Chattopadhyay A, Gurnani K, Gilbert R, Gadoury C, Iqbal U, Fatehi D, Jezierski A, Huang J, Pon RA, Sigrist M, Holt RA, Nelson BH, Atkins H, Kekre N, Yung E, Webb J, Nielsen JS, Weeratna RD.
McComb S, et al. Among authors: zhu q.
Mol Ther Oncol. 2024 Feb 13;32(1):200775. doi: 10.1016/j.omton.2024.200775. eCollection 2024 Mar 21.
Mol Ther Oncol. 2024.
PMID: 38596311
Free PMC article.